Leerink Partners Maintains Outperform on CVS Health, Lowers Price Target to $112

Benzinga · 2d ago
Leerink Partners analyst Michael Cherny maintains CVS Health (NYSE:CVS) with a Outperform and lowers the price target from $119 to $112.